DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES (Q2035396): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: import item from Italy) |
(Removed claims) |
||||||
| Property / EU contribution | |||||||
| |||||||
| Property / EU contribution: 5,714.0 Euro / rank | |||||||
| Property / budget | |||||||
| |||||||
| Property / budget: 11,428.0 Euro / rank | |||||||
| Property / co-financing rate | |||||||
| |||||||
| Property / co-financing rate: 50.0 percent / rank | |||||||
Revision as of 23:19, 8 February 2022
Project Q2035396 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES |
Project Q2035396 in Italy |
Statements
15 November 2016
0 references
7 December 2018
0 references
3 December 2018
0 references
TAKIS SRL
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
L'AZIENDA DI BIOTECNOLOGIE TAKIS PRODUCE IN MODO INNOVATIVO ED EFFICACE ANTICORPI MONOCLONALI PER CONTO PROPRIO E PER CONTO TERZI. SEBBENE MOLTO COMPETITIVA NEI PROTOCOLLI DI VACCINAZIONE, IL PROCESSO ATTUALE MANCA DI UN SISTEMA ROBOTIZZATO PER L (Italian)
0 references
THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR (English)
0 references
LA SOCIÉTÉ DE BIOTECHNOLOGIE TAKIS PRODUIT DES ANTICORPS MONOCLONAUX INNOVANTS ET EFFICACES POUR SON PROPRE COMPTE ET POUR LE COMPTE DE TIERS. BIEN QUE TRÈS COMPÉTITIF DANS LES PROTOCOLES DE VACCINATION, LE PROCESSUS ACTUEL NE DISPOSE PAS D’UN SYSTÈME ROBOTISÉ POUR (French)
16 December 2021
0 references
TAKIS BIOTECHNOLOGIE BEDRIJF PRODUCEERT INNOVATIEVE EN EFFECTIEVE MONOKLONALE ANTILICHAMEN OP EIGEN EN VOOR REKENING VAN DERDEN. HOEWEL ZEER CONCURREREND IN VACCINATIEPROTOCOLLEN, ONTBREEKT HET HUIDIGE PROCES AAN EEN GEROBOTISEERD SYSTEEM VOOR (Dutch)
23 December 2021
0 references
TAKIS BIOTECHNOLOGIE-UNTERNEHMEN PRODUZIERT INNOVATIVE UND EFFEKTIVE MONOKLONALE ANTIKÖRPER FÜR SICH ALLEIN UND IM AUFTRAG DRITTER. OBWOHL IN DEN IMPFPROTOKOLLEN SEHR KONKURRENZFÄHIG IST, FEHLT DEM DERZEITIGEN PROZESS EIN ROBOTERSYSTEM FÜR (German)
24 December 2021
0 references
LA EMPRESA BIOTECNOLÓGICA TAKIS PRODUCE ANTICUERPOS MONOCLONALES INNOVADORES Y EFICACES POR SÍ SOLOS Y EN NOMBRE DE TERCEROS. AUNQUE MUY COMPETITIVO EN LOS PROTOCOLOS DE VACUNACIÓN, EL PROCESO ACTUAL CARECE DE UN SISTEMA ROBOTIZADO PARA (Spanish)
25 January 2022
0 references
ROMA
0 references
Identifiers
F83G17000640007
0 references